Novo, a holding and investment company, completed the acquisition of Ellab, a company that provides software and hardware for validation and monitoring for the life sciences industry, from EQT Partners, a private equity firm. Financial terms were not disclosed. “Ellab’s solutions play a vital role in ensuring accuracy and compliance in its clients’ biotech and pharmaceutical processes, which is key for these companies. This was true when we first invested in Ellab and remains the case today. The difference now is the scale and flexibility that Ellab offers, as it has transformed into a full-suite provider of validation and monitoring solutions and services. It has been a privilege to partner with the entire Ellab management team, who have built a company with a strong culture and customer focus, dedication to innovation and commitment to consumer safety. We believe Novo Holdings is a great partner for the next stage of Ellab’s growth journey and we wish them all the best in the future,” Rikke Kjaer Nielsen, EQT Partner.